Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1
Public ClinicalTrials.gov record NCT02600611. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-1
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.
Study identification
- NCT ID
- NCT02600611
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 600 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 1, 2015 (Actual)
- Primary completion
- Jan 30, 2017 (Actual)
- Completion
- Jan 30, 2017 (Actual)
- Last update posted
- Jun 19, 2018
2015 – 2017
United States locations
- U.S. sites
- 16
- U.S. states
- 8
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California | Buena Park | California | 90620 | — |
| California | La Mesa | California | 91942 | — |
| California | Long Beach | California | 90806 | — |
| California | Modesto | California | 95350-449 | — |
| California | Oceanside | California | 92056 | — |
| California | Torrance | California | 90503 | — |
| District of Columbia | Washington D.C. | District of Columbia | 20017 | — |
| Florida | DeLand | Florida | 32770-0834 | — |
| Florida | Miami | Florida | 33144 | — |
| Indiana | Indianapolis | Indiana | 46260 | — |
| Nebraska | Lincoln | Nebraska | 68510-2462 | — |
| Tennessee | Franklin | Tennessee | 37067 | — |
| Tennessee | Franklin | Tennessee | 37094 | — |
| Texas | Channelview | Texas | 77530 | — |
| Texas | McAllen | Texas | 78503 | — |
| Washington | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02600611, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 19, 2018 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02600611 live on ClinicalTrials.gov.